Do you prefer using an anthracycline or non-anthracycline adjuvant regimen in BRCA+ premenopausal patients with T2N0 HR+ breast cancer?
-premenopausal
-T2N0
-BRCA1 germline PV
-ER+ (Allred 7/8) and negative for PR/HER2?
Answer from: Medical Oncologist at Academic Institution
My choice of chemotherapy for localized BRCA+ breast cancer is guided by the patient's risk factors such as tumor grade, tumor size, presence or absence of lymphovascular invasion, number of lymph nodes involved, Oncotype dx result, and the patient's age. For small, node negative, HR+, HER2- breast ...
Sign in or Register to read more